Production (Stage)
Xilio Therapeutics, Inc.
XLO
$0.8838
-$0.0132-1.47%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -13.27M | -13.09M | -14.02M | -13.93M | -17.20M |
| Total Depreciation and Amortization | 497.00K | 375.00K | 381.00K | 445.00K | 443.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.54M | 1.52M | 1.58M | 1.51M | 1.83M |
| Change in Net Operating Assets | 40.21M | -2.96M | -1.61M | 31.92M | 4.43M |
| Cash from Operations | 28.98M | -14.16M | -13.67M | 19.95M | -10.50M |
| Capital Expenditure | -22.00K | -6.00K | -9.00K | -21.00K | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -22.00K | -6.00K | -9.00K | -21.00K | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 0.00 | -7.00K | -21.00K | -3.35M |
| Issuance of Common Stock | 4.83M | 8.20M | 4.00K | 20.06M | 4.31M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 4.83M | 8.20M | -3.00K | 20.04M | 954.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 33.79M | -5.96M | -13.68M | 39.98M | -9.55M |